SCHEMBL513310

SCHEMBL513310

CC(C)(C)OC(=O)N1CCC(=CC(=O)Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.48
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ESR2 Q92731 1/20 0.43
ADORA1 P30542 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
NR1H2 P55055 1/20 0.42
HPGD P15428 1/20 0.41
EPHX2 P34913 1/20 0.40
POLB P06746 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
STS P08842 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2948300 0.85 USP2 (0.49) GRM5USP2SMN1; SMN2MEN1KMT2A
SCHEMBL14419067 0.85 USP2 (0.49) GRM5USP2SMN1; SMN2MEN1KMT2A
SCHEMBL843458 0.85 USP2 (0.49) GRM5USP2SMN1; SMN2MEN1KMT2A
SCHEMBL106354 0.83 USP2 (0.46) GRM5USP2SMN1; SMN2ESR2ADORA1
SCHEMBL24673913 0.81 USP2 (0.51) GRM5USP2SMN1; SMN2MEN1KMT2A
SCHEMBL10253506 0.81 USP2 (0.51) GRM5USP2SMN1; SMN2MEN1KMT2A
SCHEMBL7603660 0.81 USP2 (0.45) GRM5USP2SMN1; SMN2ESR2ADORA1
SCHEMBL4078273 0.81 USP2 (0.45) GRM5USP2SMN1; SMN2ESR2ADORA1
SCHEMBL3714994 0.81 USP2 (0.47) GRM5USP2SMN1; SMN2MEN1KMT2A
SCHEMBL30897992 0.80 USP2 (0.50) GRM5USP2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477981-A1 HETEROCYCLIC MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2012-07-25 EP disclosed
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 GRM5 2/4885USP2 3153/4885SMN1; SMN2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.